Motilal Oswal initiated coverage on Molbio Diagnostics with a Buy rating and ₹1,800 target, implying 21% upside. The brokerage sees strong growth potential from decentralised molecular diagnostics, led by Molbio’s Truenat platform, which has 12,500+ devices across 90+ countries and 43 assays for 30 diseases.
More in Economy
US EIA lifts Brent forecast to $98 as Iran war tightens global supplies
October 6, 2026
Fed plans bank-supervision overhaul to strengthen accountability, says Vice Chair Michelle Bowman
October 6, 2026
US software shares hit 2026 highs as AI disruption fears ease
October 6, 2026
Sebi says Jane Street’s appeal for more details a delaying ploy
October 6, 2026
Banks vs NBFCs: Which stocks could benefit as RBI eyes rate hike for first time in 3 years?
October 6, 2026
Jane Street denies manipulation charges in India appeal case
October 6, 2026
Latest News
இனி மேற்குவங்காளம் என்ற பெயர் கிடையாது.. மாநிலத்தின் பெயரை மாற்ற ரெடியான பாஜக அரசு! பின்னணி
October 6, 2026
இஷான் கிஷனுக்கு வாழ்வு கொடுத்த 3-வது அம்பயர்.. வேதனையில் சிரித்த வெஸ்ட் இண்டீஸ் வீரர்கள்
October 6, 2026
US EIA lifts Brent forecast to $98 as Iran war tightens global supplies
October 6, 2026
The best deals under $25 during October Prime Day
October 6, 2026
ஒரு வழியா.. நல்ல செய்தியை சொன்ன WHO! ரஷ்யாவை நினைத்து உலக மக்கள் கவலைப்பட வேண்டாம்!
October 6, 2026
Fed plans bank-supervision overhaul to strengthen accountability, says Vice Chair Michelle Bowman
October 6, 2026